StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for VTVT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $33.32 | $38.43 | +15.34% | 0.1M |
| 05-15 | $38.35 | $35.70 | -6.92% | 0.0M |
| 05-18 | $34.37 | $35.49 | +3.27% | 0.0M |
| 05-19 | $34.96 | $36.49 | +4.38% | 0.1M |
| 05-20 | $36.99 | $36.60 | -1.05% | 0.1M |
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $36.84M | $0.00 | $0.00 | $0.00 |
Operating Income | $23.26M | $-32.81M | $-24.92M | $-14.22M |
Net Income | $24.13M | $-26.97M | $-19.84M | $-11.14M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $98.81M | $89.90M | $99.49M | $26.45M |
Total Liabilities | $8.85M | $25.46M | $28.95M | $24.04M |
Cash & Equivalents | $98.09M | $88.93M | $98.50M | $25.92M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | Not available | Not available | Not available |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.